[KBIC 2019] Biorchestra Challenges Development of Alzheimer's Therapies Using RNA Technology

14 January 2020

Enter 03/09/2019 15:33  modified 09/03/2019 15:38

"The development of the brain in toxic and Alzheimer's candidate (pipeline) for the treatment of dementia in a way that eliminates the inflammation factors."

Ryu jin-hyeob Biorchestra representatives held in Yongsan, Seoul Dragon City late last month, 2019 Republic of Korea Bio Investment Conference (KBIC) said. The company has a new drug pipeline that binds microRNAs (ribonucleic acids) that are specifically expressed in patients with Alzheimer's dementia to inhibit toxic proteins.

The company's approach is different from traditional global pharmaceutical companies. Candidates for eliminating the increasing beta amyloid protein have been developed in patients with Alzheimer's dementia, but the string drank the failure. Candidates being developed by bioorchestra treat dementia by activating certain proteins in immune cells to eliminate toxic and inflammatory factors in the brain.

Bioorchestra isn't the only one looking for a solution for specific proteins in immune cells. Genalitech's denaliterapitics is developing a therapeutic agent, noting that a protein called Trem2 in the cell membrane is involved in immune cell activation.

Bioorchestra has also found ways to facilitate the passage of drugs through the blood brain barrier (BBB). Mr. Ryu said, "I coated certain substances that are widely distributed in the brain and confirmed that the brain permeated well."

The company is developing a brain tumor treatment system. Ryu said it is "a level of basic research."

By Park Young-tae, Reporter Lee In-hyuk

Ⓒ, All Rights Reserved

기사 원문보기